Literature DB >> 20302301

Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.

Wenyan Wu1, Rongti Li, Subbalakshmi S Malladi, Hemamali J Warshakoon, Matthew R Kimbrell, Michael W Amolins, Rehman Ukani, Apurba Datta, Sunil A David.   

Abstract

The N-termini of bacterial lipoproteins are acylated with a (S)-(2,3-bisacyloxypropyl)cysteinyl residue. Lipopeptides derived from lipoproteins activate innate immune responses by engaging Toll-like receptor 2 (TLR2) and are highly immunostimulatory and yet without apparent toxicity in animal models. The lipopeptides may therefore be useful as potential immunotherapeutic agents. Previous structure-activity relationships in such lipopeptides have largely been obtained using murine cells, and it is now clear that significant species-specific differences exist between human and murine TLR responses. We have examined in detail the role of the highly conserved Cys residue as well as the geometry and stereochemistry of the Cys-Ser dipeptide unit. (R)-Diacylthioglycerol analogues are maximally active in reporter gene assays using human TLR2. The Cys-Ser dipeptide unit represents the minimal part-structure, but its stereochemistry was found not to be a critical determinant of activity. The thioether bridge between the diacyl and dipeptide units is crucial, and replacement by an oxoether bridge results in a dramatic decrease in activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20302301      PMCID: PMC2859677          DOI: 10.1021/jm901839g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  62 in total

1.  Involvement of innate immunity in the pathogenesis of intestinal Behçet's disease.

Authors:  K Nara; M S Kurokawa; S Chiba; H Yoshikawa; S Tsukikawa; T Matsuda; N Suzuki
Journal:  Clin Exp Immunol       Date:  2008-03-10       Impact factor: 4.330

Review 2.  Innate immunity: impact on the adaptive immune response.

Authors:  R Medzhitov; C A Janeway
Journal:  Curr Opin Immunol       Date:  1997-02       Impact factor: 7.486

3.  A synthetic analogue of Escherichia coli lipoprotein, tripalmitoyl pentapeptide, constitutes a potent immune adjuvant.

Authors:  A Lex; K H Wiesmüller; G Jung; W G Bessler
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

Review 4.  Lipoteichoic acid and lipids in the membrane of Staphylococcus aureus.

Authors:  W Fischer
Journal:  Med Microbiol Immunol       Date:  1994-05       Impact factor: 3.402

5.  Identification of male-specific chiral compound from the sugarcane weevil Sphenophorus levis.

Authors:  Paulo H G Zarbin; Enrico de Beni Arrigoni; Aurélia Reckziegel; Jardel A Moreira; Patrícia T Baraldi; Paulo C Vieira
Journal:  J Chem Ecol       Date:  2003-02       Impact factor: 2.626

6.  Human but not murine toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides.

Authors:  Alina Grabiec; Guangxun Meng; Sylvia Fichte; Wolfgang Bessler; Hermann Wagner; Carsten J Kirschning
Journal:  J Biol Chem       Date:  2004-09-01       Impact factor: 5.157

Review 7.  Twelve immunotherapy drugs that could cure cancers.

Authors:  Martin A Cheever
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

8.  Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells.

Authors:  Matthew R Kimbrell; Hemamali Warshakoon; Jens R Cromer; Subbalakshmi Malladi; Jennifer D Hood; Rajalakshmi Balakrishna; Tandace A Scholdberg; Sunil A David
Journal:  Immunol Lett       Date:  2008-04-18       Impact factor: 3.685

9.  New strategy for the construction of a monotetrahydrofuran ring in Annonaceous acetogenin based on a ruthenium ring-closing metathesis: application to the synthesis of Solamin.

Authors:  Guillaume Prestat; Christophe Baylon; Marie-Pierre Heck; Gabriela A Grasa; Steven P Nolan; Charles Mioskowski
Journal:  J Org Chem       Date:  2004-08-20       Impact factor: 4.354

Review 10.  The peptidoglycan recognition proteins (PGRPs).

Authors:  Roman Dziarski; Dipika Gupta
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

View more
  30 in total

1.  Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Authors:  Geetanjali Agnihotri; Breanna M Crall; Tyler C Lewis; Timothy P Day; Rajalakshmi Balakrishna; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2011-11-04       Impact factor: 7.446

2.  A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.

Authors:  Chunmei Cheng; Pooja Jain; Ilham Bettahi; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-07-08       Impact factor: 3.641

3.  Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity.

Authors:  Rui Zhang; Jake S Kramer; Josiah D Smith; Brittany N Allen; Caitlin N Leeper; Xiaolei Li; Logan D Morton; Fabio Gallazzi; Bret D Ulery
Journal:  AAPS J       Date:  2018-06-01       Impact factor: 4.009

4.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Authors:  Deepak B Salunke; Nikunj M Shukla; Euna Yoo; Breanna M Crall; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2012-03-15       Impact factor: 7.446

Review 5.  Strategies for designing synthetic immune agonists.

Authors:  Tom Y-H Wu
Journal:  Immunology       Date:  2016-07-11       Impact factor: 7.397

6.  Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.

Authors:  Rehman Ukani; Tyler C Lewis; Timothy P Day; Wenyan Wu; Subbalakshmi S Malladi; Hemamali J Warshakoon; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2011-11-09       Impact factor: 2.823

7.  Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Authors:  Deepak B Salunke; Seth W Connelly; Nikunj M Shukla; Alec R Hermanson; Lauren M Fox; Sunil A David
Journal:  J Med Chem       Date:  2013-07-10       Impact factor: 7.446

8.  Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Authors:  Hari Prasad Kokatla; Euna Yoo; Deepak B Salunke; Diptesh Sil; Cameron F Ng; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Lauren M Fox; Sunil A David
Journal:  Org Biomol Chem       Date:  2013-02-21       Impact factor: 3.876

9.  Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.

Authors:  Deepak B Salunke; Euna Yoo; Nikunj M Shukla; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Katelyn J Serafin; Victor W Day; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2012-09-07       Impact factor: 7.446

10.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.